China Tightens Probiotic Health Food Regulations, Increases CFU & Strain Specificity
China's SAMR has drafted new probiotic health food regulations, increasing minimum CFUs and mandating strain-specific data, impacting market entry and product formulation. Public consultation is open until 24 August 2026.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Beijing, China — 03 August 2026
China's State Administration of Market Regulation (SAMR) has issued new draft regulations for probiotic health foods, open for public consultation until 24 August 2026. These proposed laws are set to replace the existing "Declaration and Review of Probiotic Health Food (Trial)" framework, introducing five key changes aimed at enhancing product quality and traceability. The revisions will necessitate increased minimum colony-forming units (CFU) throughout a product's shelf life and demand explicit identification of probiotic strains, their functionalities, and genetic stability.
SAMR asserts that these measures are critical for ensuring strain traceability and robust quality control within China's rapidly expanding probiotic market. The heightened regulatory scrutiny implies significant operational adjustments for both domestic and international manufacturers and brand owners operating in or looking to enter the Chinese health food sector. Companies will need to re-evaluate their current formulations, supply chain verification processes, and product registration strategies to align with the more stringent requirements.
Beyond regulatory changes, intellectual property for specific probiotic strains continues to be a strategic asset. The Akkermansia Company (TAC), recently acquired by Danone, has secured a new U.S. patent from the United States Patent and Trademark Office. This patent covers the use of Akkermansia for metabolic disorders, including methods for promoting weight loss through oral administration of substantially purified forms, encompassing both live and pasteurised cells. This expands TAC's enforceable protection in the U.S. market, signifying the increasing value placed on specific strain IP in functional ingredients.
In parallel, the supplement sector has seen a notable financial development with IM8 securing a $1 billion growth financing deal from General Catalyst's Customer Value Fund (CVF). This unconventional funding structure allows General Catalyst to front 70% of IM8's monthly marketing investment, accelerating international expansion and product portfolio diversification just 19 months post-launch. The deal underscores a growing trend of innovative financing models designed to fuel aggressive market penetration and R&D in high-growth supplement brands.
What this means for China
Manufacturers and brand owners operating in China must initiate immediate reviews of their probiotic formulations to ensure compliance with the increased minimum CFU count and the mandatory strain specification. Failure to meet the 24 August 2026 public consultation deadline and subsequent implementation could lead to market exclusion or significant product recall costs. Investment in robust analytical testing for genetic stability and strain verification will become essential. This regulatory shift presents an opportunity for brands with scientifically backed, well-documented probiotic strains to gain a competitive edge by demonstrating superior quality and compliance, potentially allowing for premium pricing and enhanced market share against less prepared competitors.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.